Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Repligen Corp 41 SEYON STREET BUILDING 1 SUITE 100 WALTHAM MA 02453 USA

www.repligen.com Employees: 1,783 P: 781-250-0111 F: 781-250-0115

Description:

Repligen Corporation is a leading provider of advanced bioprocessing technologies and solutions used by large biopharmaceutical companies and contract manufacturing organizations for manufacturing biologic drugs, such as monoclonal antibodies (mAbs) and gene therapies. Repligen earns revenues from the sale of several products, which can be categorized mainly under three segments, namely Filtration, Chromatography and Protein products. The chromatography products include OPUS and OPUS PD chromatography columns, chromatography resins and ELISA test kits. Filtration products consist of XCell Alternating Tangential Flow (ATF) Systems and consumables, KrosFlo filtration products and SIUS filtration products. Protein products comprise the Protein A ligands and cell culture growth factors.

Key Statistics

Overview:

Market Capitalization, $K 8,093,661
Enterprise Value, $K 7,411,791
Shares Outstanding, K 56,027
Annual Sales, $ 638,760 K
Annual Net Income, $ 41,580 K
Last Quarter Sales, $ 154,870 K
Last Quarter Net Income, $ -650 K
EBIT, $ -5,200 K
EBITDA, $ 65,330 K
60-Month Beta 0.96
% of Insider Shareholders 1.20%
% of Institutional Shareholders 97.64%
Float, K 55,355
% Float 98.80%
Short Volume Ratio 0.57

Growth:

1-Year Return -19.66%
3-Year Return -45.41%
5-Year Return 56.63%
5-Year Revenue Growth 229.21%
5-Year Earnings Growth 139.73%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.43 on 11/12/24
Next Earnings Date N/A
Earnings Per Share ttm 1.37
EPS Growth vs. Prev Qtr 30.30%
EPS Growth vs. Prev Year 86.96%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RGEN Ratios

Ratio
Price/Earnings ttm 106.96
Price/Earnings forward 94.86
Price/Earnings to Growth 4.34
Return-on-Equity % 3.90%
Return-on-Assets % 2.72%
Profit Margin % 6.51%
Debt/Equity 0.00
Price/Sales 12.85
Price/Cash Flow 48.30
Price/Book 4.07
Book Value/Share 36.01
Interest Coverage 33.89
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar